Electronic Supplementary Material (ESI) for Organic & Biomolecular Chemistry. This journal is © The Royal Society of Chemistry 2021

An Easy and Practical Approach to Access Multifunctional Cylcopentadiene- and Cyclopentene-Spirooxindoles via [3+2] Annulation

Prakash K. Warghude,^a Abhijeet S. Sabale,^a Ruchi Dixit,^{b,c} Kumar Vanka^{b,c} and Ramakrishna G. Bhat^{*a}

^aDepartment of Chemistry, Main Building, Indian Institute of Science Education and Research (IISER)-Pune, Dr. Homi Bhabha Road, Pashan, Pune, 411008, Maharashtra, India

^bPhysical and Material Chemistry Division, CSIR-National Chemical Laboratory, Dr. Homi Bhabha Road, Pashan, Pune - 411008 India

^cAcademy of Scientific and Innovative Research (AcSIR), Ghaziabad – 201002, India

rgb@iiserpune.ac.in

| 1. | General Experimental Section |
|----|---|
| 2. | General procedure for the synthesis of spirooxindole cyclopentadiene – GP-1S3 |
| 3. | General procedure for the synthesis of Bis-spirocyclic oxindole – GP-2S3 |
| 4. | General procedure for the synthesis of dispiro[benzo[b]thiophene – GP-3S4 |
| 5. | Screening of chiral catalysts and solvents |
| 6. | Mechanistic Study |
| | A. Control Experiments |
| | B. Procedure for ¹⁸ O labelling experiment |
| | C. Detection of intermediate |
| | D. Computational detail |
| 7. | Experimental DataS16-S43 |
| 8. | Copies of ¹ H and ¹³ C Spectra |
| 9. | Crystallographic data |

General Experimental Section

Unless otherwise stated, all the reagents were purchased from commercial suppliers (Aldrich, TCI, Alfa Aesar, and Spectrochem) and used without purification. All the reactions were carried out in oven dried glassware. Thin-layer chromatography (TLC) was performed using silica gel 60 GF₂₅₄ pre-coated aluminum backed plates (2.5 mm). Visualization was accomplished by irradiation with UV light at 254 nm and the solution of Phosphomolybdic Acid (PMA), KMnO₄ was used to stain products. The column chromatography was performed using silica gel (100-200 mesh) eluting with petroleum ether and ethyl acetate. The NMR spectra were recorded using tetramethylsilane as the internal standard. ¹H NMR spectra were recorded at 400 MHz, and ¹³C NMR spectra were recorded at 100 MHz (Bruker and Jeol). Chemical shifts (δ) are reported in ppm downfield from CDCl₃ (δ = 7.26 ppm) for ¹H NMR and relative to the central CDCl₃ resonance ($\delta = 77.16$ ppm) for ¹³C NMR spectroscopy. For ¹H NMR, data are reported as follows: chemical shift, multiplicity (s = $\frac{1}{2}$ singlet, d = doublet, dd = doublet doublet, t = triplet, q = quartet, br = broad, m = multiplet), coupling constants (J) are given in Hz and integration. All the samples were analyzed by high resolution mass spectrometer (HRMS) using ESI TOF. Melting points were measured using BÜCHI M-560 melting point apparatus. All melting points were measured in open glass capillary and values are uncorrected. Morita-Baylis-Hillman carbonates 1a-1j were prepared according to the literature procedure.¹ Substituted aurones **2a-2t** were synthesized according to the literature procedure.² Thioaurones **2aa-2ha** were synthesized according to the literature procedure.³

References

- 1. X. Fan, H. Yang and M. Shi. Adv. Synth. Catal. 2017, 359, 49-57.
- 2. Z. P. Wang, S. Xiang, P. L. Shao and Y. J. He, Org. Chem. 2018, 83, 10995-11007.
- 3. T. B. Nguyen and P. Retailleau, Org. Lett. 2018, 20, 186–189.

General procedure for the synthesis of spirooxindole cyclopentadiene - GP-1



To the stirred solution of Morita-Baylis-Hillman carbonate of isatin **1a** (0.115 mmol, 1.0 equiv.), aurone **2a** (0.138 mmol, 1.2 equiv.) in 2 mL of acetonitrile, DMAP (0.023 mmol, 0.2 equiv.)* was added at room temperature. Then the resulting reaction mixture was stirred for 24 h at room temperature* or as indicated in manuscript (see Manuscript, Scheme 2, Reaction conditions). After completion of the reaction (monitored by TLC), solvent was evaporated under reduced pressure and the residue was purified on silica gel (100-200 mesh) column chromatography (petroleum ether/ethyl acetate).

*Synthesis of *ortho* derivatives: **3t** required 20 mol% DMAP at 50 °C or 100 mol% DMAP; **3u** required 100 mol% DMAP at 70 °C and **3v** required 50 mol% DMAP at 70 °C

General procedure for the synthesis of Bis-spirocyclic oxindole – GP-2



To the stirred solution of Morita-Baylis-Hillman carbonate of isatin **1a** (0.115 mmol, 1.0 equiv.), substituted aurones (**2k** or **2l** or **2m**) (0.138 mmol, 1.2 equiv.) in 2 mL of acetonitrile, DMAP (0.023 mmol, 0.2 equiv.) was added at room temperature. Then the resulting mixture was stirred for 24 h at room temperature. After completion of the reaction (monitored by TLC), solvent was evaporated under reduced pressure and the residue was purified on silica gel (100-200 mesh) column chromatography (petroleum ether/ethyl acetate).





To the stirred solution of Morita-Baylis-Hillman carbonate of isatin **1a** (0.115 mmol, 1.0 equiv.), thioaurone **2aa** (0.138 mmol, 1.2 equiv.) in 2 mL of acetonitrile, DBU (0.115 mmol, 1.0 equiv.) was added at room temperature. Then the resulting mixture was stirred for 24 h at room temperature. After completion of the reaction (monitored by TLC), solvent was evaporated under reduced pressure and the residue was purified on silica gel (100-200 mesh) column chromatography (petroleum ether/ethyl acetate).



Appendix I: Screening of chiral catalysts and solvents

| Entry | Catalysts | Solvent | Temp (°C) | Time (h) | Yield (%) |
|-------|-----------|---------------------------------|-----------|----------|-----------|
| 1 | А | CH ₂ Cl ₂ | rt | 36 | N.R |
| 2 | В | CH_2Cl_2 | rt | 48 | N.R |
| 3 | С | CH_2Cl_2 | rt | 72 | N.R |
| 4 | А | Toluene | 0 | 24 | N.R |
| 5 | А | Toluene | -20 | 24 | N.R |
| 6 | А | Toluene | 60 | 24 | N.R |
| 7 | D | CH_2Cl_2 | rt | 48 | N.R |
| 8 | Ε | CH_2Cl_2 | rt | 48 | N.R |
| 9 | E | CHCl ₃ | 0 | 36 | N.R |
| 10 | E | CH ₃ CN | -20 | 36 | N.R |
| 11 | E | CH ₃ CN | -40 | 24 | N.R |
| 12 | Е | CHCl ₃ | 60 | 24 | N.R |
| 13 | F | CH_2Cl_2 | rt | 36 | N.R |
| 14 | A+E | CH ₂ Cl ₂ | rt | 36 | N.R |

Reaction conditions: "The reactions were carried out with **1a** (0.115 mmol, 40 mg), **2a** (0.138 mmol, 26 mg), Cat. (20 mol %) in 2.0 mL of solvent at specified temperature for the specified time. N.R = No reaction

Mechanistic Studies:

A. Control Experiments



Reaction conditions- MBH carbonate of isatin **1a** (40 mg, 0.115 mmol), thioaurone **2aa** (33 mg, 0.138 mmol), DBU (17 mg, 0.115 mmol), 2,2,6,6-tetramethylpiperidine-1-oxyl (TEMPO, 2 equiv.) or Butylated hydroxyl toluene (BHT, 2 equiv.), acetonitrile (2.0 mL) were added in a 10 mL round bottom flask and the reaction mixture was stirred under air at room temperature for 24 h. These control experiments afforded compound **4a** in 50-52% yields respectively after purification by column chromatography (See Table above).

B. Procedure for ¹⁸O labelling experiment:



In an oven dried 20 mL crimp cap vial Morita-Baylis-Hillman carbonate of isatin **1a** (0.115 mmol, 1.0 equiv.), thioaurone **2aa** (0.138 mmol, 1.2 equiv.) were added at room temperature

under argon atmosphere. The vial was purged with argon and sealed with aluminium crimp cap using a crimper. Then 2 mL of dry acetonitrile was added under argon. To this solution DBU (0.115 mmol, 1.0 equiv.) was added under argon and immediately the reaction vial was filled and purged with ¹⁸O₂ gas (98% isotopic purity) and kept it for stirring for 24 h. The percentage of ¹⁸O enrichment product **4aa** was examined by HRMS (ESI TOF, +ve ion mode) as shown Figure 1. The calculated data showed 52% of ¹⁸O enrichment in **4aa**. **HRMS** (ESI TOF) m/z calcd. For C₂₈H₂₁NO₄ ¹⁸OS [M+H]⁺ 486.1261, found 486.1260



Figure 1. HRMS spectrum of 4aa-¹⁸O enriched product

C. Detection of intermediate

In an oven dried 20 mL crimp cap vial, Morita-Baylis-Hillman carbonate of isatin **1a** (0.115 mmol, 1.0 equiv.), thioaurone **2aa** (0.138 mmol, 1.2 equiv.) were added at room temperature under argon atmosphere. The vial was purged with argon and sealed with aluminium crimp cap using a crimper. Then 2 mL of dry acetonitrile was added under argon. To this solution DBU (0.115 mmol, 1.0 equiv.) was added under argon (to maintain dry and inert atmosphere). After the compete addition of reagents the reaction vial was filled and purged with argon and kept it for stirring for 24 h. After which, the reaction sample was analysed for HRMS.

The ESI-MS of crude reaction mixture shown Figure 2. Intermediate E was detected based on HRMS. **HRMS** (ESI TOF) m/z calcd. For C₂₈H₂₁NO₄S [M+H]⁺ 468.1269, found 468.1262



Figure 2. HRMS spectrum of intermediate E

D. Computational Details:

All the calculations in this study have been performed with density functional theory (DFT), using Turbomole 7.1 suite of programs,¹ using the PBE functional². The TZVP³ basis set has been employed. The resolution of identity (RI),⁴ along with the multipole accelerated resolution of identity (marij)⁵ approximations have been employed for an accurate and efficient treatment of the electronic Coulomb term in the DFT calculations. Solvent corrections were incorporated with optimization calculations using the COSMO model⁶ with acetonitrile ($\varepsilon = 37.5$) as the solvent. Also, intrinsic reaction coordinate (IRC)⁷ calculations were done with all the transition states to further confirm that they were the correct transition state, yielding the correct reactant and product structures. The values reported are ΔG values, with zero-point energy corrections, internal energy and entropic contributions were included through frequency calculations on the optimized minima, with the temperature taken to be 298.15 K. Harmonic frequency calculations were performed for all stationary points to confirm them as local minima or transition state structures. Then, to find the efficiency of the catalytic cycle in our mechanism, we have calculated the relative efficiency with the AUTOF^{8,9} program by employing the "Energetic Span Model" (ESM), developed by Shaik and co-workers¹⁰⁻¹² on all the free energy profiles discussed in the manuscript. The turnover frequency (TOF) calculations take into account the principal rate-determining transition state, potentially rate-influencing transition states and intermediates during the catalysis process. TOF is calculated by the following equation:

 $TOF = \frac{KBT}{h} e^{-\delta E/RT}$

 $\delta E = T_{TDTS} - I_{TDI}$ If TDTS appears after TDI $\delta E = T_{TDTS} - I_{TDI} - \Delta G_r$ If TDTS appears before TDI

This model has been employed to calculate the TOFs for the free energy profiles obtained for the mechanisms in the solvent phase discussed in the manuscript. This model can also be employed for stoichiometric reactions, where the TOF would correspond to the efficiency of the reaction.

Results and Discussion:

In order to understand the mechanism of the [3+2] annulation of the Morita-Baylis-Hillman (MBH) carbonates of isatin with aurone/thioaurone in the presence of a Lewis base, we have done full quantum chemical calculations using density functional theory (DFT). We have chosen DMAP and DBU for the calculations, because the obtained product yield was the highest for these Lewis bases.

For the case of aurones as shown in Scheme 2, DMAP has been taken as the Lewis base and *ortho*-substituted (2k) as well as *para*-substituted aurone (2c) are being considered in the study.

For the *ortho* case, in the first step, DMAP can react with **1a** to give **Int_1**. The nucleophilic DMAP attacks on the MBH carbonate **1a** to form the quaternary ammonium salt **I**, which is a thermodynamically unstable ($\Delta G = 12.7 \text{ kcal/mol}$) process, (see **Figure 3** below) formed along with the evolution of carbon dioxide and *tert*-butoxide. The *in situ* generated *tert*-butoxide, in turn, reacts with the quaternary ammonium salt **I** to give an allylic nitrogen ylide **I**. Subsequently, in the second step, **I**' reacts with the aurone **2k** to generate an intermediate **II** with the reaction free energy (ΔG) being -21.5 kcal/mol. This is followed by an intramolecular Michael addition in the third step, leading to the intermediate **III** by eliminating DMAP, with the reaction free energy (ΔG) being -29.5 kcal/mol. Subsequently, in the fourth step, DMAP abstracts the proton from intermediate **III**, leading to the formation of the phenoxide intermediate **IV** *via* ring-opening, with the reaction free energy (ΔG) being unstable by 1.5 kcal/mol. Finally, in the last step, intermediate **IV** leads to the desired compound **3t'**, with reaction free energy (ΔG) being -6.5 kcal/mol *via* protonation and regeneration of DMAP, to complete the catalytic cycle.

A similar mechanism pathway is seen to be followed for the case of the *para*-substituted aurone 2c (see the Manuscript).



Figure 3. The reaction mechanism for the annulation with the *ortho*-substituted aurone, calculated at the PBE/TZVP level of theory. ΔG (in kcal/mol) represents the Gibbs free energy of the reaction. The thermodynamics for the cycle is shown in this scheme.

Experimentally, it was found that to achieve product (**3t**') in the *ortho*-substituted aurone **2k** case, a higher concentration of Lewis base, or a higher temperature was required, whereas, for the case of *para*-substituted aurone **2c**, product (**3l**) was achieved at room temperature. It can be seen from the calculations that the formation of intermediate **IV** from intermediate **III** in the case *ortho*-substituted **2k** is unstable by 1.5 kcal/mol whereas, for the *para*-substituted case, it is favorable by 2.0 kcal/mol. To do a detailed study, we have also calculated the transition states, and thus the barriers, for both the cases from intermediate **III** to intermediate **IV**, as shown in Figure **4a** and Figure **4b** below. If we compare both mechanisms, the barrier for **TS**_1 with respect to intermediate **III** is 15.7 kcal/mol for the *para* case, whereas for the *ortho*-substituted case, it is 16.9 kcal/mol, which is approximately 1.2 kcal/mol higher than the *para*-substituted mechanism. Furthermore, in order to check the efficiency of the catalytic cycle, we have also calculated the turnover frequency (TOF) for both the processes. It is to be noted that in the current case, the TOF has been calculated with an assumption: that the barriers for all the steps for the two cases studied: *ortho*-substituted as well as *para*-substituted aurone **2**, are similar. This assumption is based on calculations of the relative

barriers for the transformation from **III** to **IV** for both the cases, which were seen to be almost the same. Since this is the critical step in this process (occurs for the *para*-substituted aurone, but not for the *ortho*-substituted case), the similarity in the barriers suggests that considering the rest of the barriers in the two cycles to be similar is a reasonable assumption.

The TOF values (**Appendix II**) indicate that the mechanism with the *para*-substituted aurone is approximately 6.4 times more efficient than for the *ortho*-substituted aurone.

Appendix II. The values for the turnover frequencies (TOFs) obtained for both *ortho* and *para*-substituted aurones **2**.

| Mechanism | Turnover Frequency (TOF) |
|-----------------------------|---------------------------------------|
| ortho substituted aurone 2k | 3.01 s ⁻¹ |
| para substituted aurone 2c | 1.93* 10 ¹ s ⁻¹ |

Figure 4a. The reaction mechanism for the annulation with the *ortho*-substituted aurone, calculated at the PBE/TZVP level of theory and ΔG (in kcal/mol) represents Gibbs free energy of the reaction. The kinetics for the cycle is shown in this scheme.

Figure 4b. The reaction mechanism for the annulation with the *ortho*-substituted aurone, calculated at the PBE/TZVP level of theory. ΔG (in kcal/mol) represents the Gibbs free energy of the reaction. The kinetics for the cycle is shown in this scheme.

References:

- TURBOMOLE V7.1 2016, a development of University of Karlsruhe and ForschungszentrumKarlsruhe GmbH, 1989-2007, TURBOMOLE GmbH, since 2007; available from http://www.turbomole.com.
- 2. Perdew, J. P.; Burke, K.; Ernzerhof, M. Phys. Rev. Lett. 1996, 77, 3865.
- 3. Ansgar, S.; Christian, H.; Reinhart, A. J. Chem. Phys. 1994, 100, 5829.
- Eichkorn, K.; Treutler, O.; Öhm, H.; Häser, M.; Ahlrichs, R. Chem. Phys. Lett. 1995, 240, 283.
- 5. Sierka, M.; Hogekamp, A.; Ahlrichs, R. J. Chem. Phys. 2003, 118, 9136.
- 6. Klamt, A.; Schüürmann, G. J. Chem. Soc., Perkin Trans. 2 1993, 799.
- 7. K. Fukui, Acc. Chem. Res. 1981, 14, 363.
- 8. S. Kozuch, J. M. L. Martin, ACS Catal. 2011, 1, 246.
- 9. A. Uhe, S. Kozuch, S. Shaik, Comput. Chem. 2010, 32, 978.
- 10. S.Kozuch, WIREs Comput. Mol. Sci. 2012, 2, 795.
- 11. A. Uhe, S.Kozuch, S. Shaik, J. Comput. Chem. 2011, 32, 978.
- 12. S. Kozuch, S. Shaik, Acc. Chem. Res. 2010, 44, 101.

Experimental Data:

Methyl -2-(2-hydroxybenzoyl)-1'-methyl-2'-oxo-3-phenyl spiro[cyclopentane-1, 3'indoline]-2, 4-diene-5-carboxylate (3a)

The compound **3a** was prepared following the general procedure **GP-1**

Yellow solid (40 mg, 76%), $R_f = 0.15$ (petroleum ether/EtOAc 70:30), MP: 171-173 °C. ¹H NMR (400 MHz, CDCl₃) δ 11.45 (s, 1H), 7.84 (s, 1H), 7.36 – 7.26 (m, 3H), 7.24 – 7.14 (m, 5H), 6.98 – 6.85 (m, 3H), 6.76 (d, J = 8.6 Hz, 1H), 6.42 – 6.35 (m, 1H), 3.65 (s, 3H), 3.39 (s, 3H). ¹³C{¹H} NMR (100 MHz, CDCl₃): δ (ppm) 196.6, 170.9, 162.4, 161.8, 150.9, 146.2, 145.5, 142.5, 141.8, 136.3, 132.7, 132.3, 129.6, 129.4, 128.6, 128.6, 123.3, 122.5, 122.5, 118.7, 118.6, 117.7, 109.0, 70.3, 52.0, 27.4. HRMS (ESI TOF) *m*/*z* calcd. For C₂₈H₂₂NO₅ [M+H]⁺ 452.1498, found 452.1501

Methyl -2-(2-hydroxybenzoyl)-1', 5'-dimethyl-2'-oxo-3-phenylspiro[cyclopentane-1, 3'indoline]-2, 4-diene-5-carboxylate (3b)

The compound 3b was prepared following the general procedure GP-1

Yellow solid (39 mg, 72%), $R_f = 0.24$ (petroleum ether/EtOAc 70:30), MP: 167-169

°C. ¹H NMR (400 MHz, CDCl₃) δ 11.45 (s, 1H), 7.83 (s, 1H), 7.34 – 7.29 (m, 2H), 7.24 – 7.14 (m, 5H), 7.07 (d, *J* = 7.9 Hz, 1H), 6.83 – 6.71 (m, 3H), 6.39 (t, *J* = 7.6 Hz, 1H), 3.66 (s, 3H), 3.36 (s, 3H), 2.18 (s, 3H). ¹³C{¹H} NMR (100 MHz, CDCl₃): δ (ppm) 196.8, 170.9, 162.5, 162.0, 150.9, 146.2, 143.3, 142.7, 142.1, 136.4, 132.9, 132.5, 132.1, 129.9, 129.7, 128.7, 123.5, 123.4, 118.9, 118.7, 117.8, 108.8, 70.6, 52.1, 27.6, 21.2. HRMS (ESI TOF) *m/z* calcd. For C₂₉H₂₄NO₅ [M+H]⁺ 466.1654, found 466.1656

Methyl-2-(2-hydroxybenzoyl)-5'-methoxy-1'-methyl-2'-oxo-3-phenylspiro[cyclopentane-1, 3'-indoline]-2, 4-diene-5-carboxylate (3c)

The compound **3c** was prepared following the general procedure **GP-1**.

Yellow solid (38 mg, 69%), $R_f = 0.15$ (petroleum ether/EtOAc 70:30), MP: 156-158 °C. ¹H NMR (400 MHz, CDCl₃) δ 11.46 (s, 1H), 7.83 (s, 1H), 7.34 – 7.29 (m, 2H), 7.23 – 7.15 (m, 5H), 6.85 – 6.74 (m, 3H), 6.52 (d, J = 2.3 Hz, 1H), 6.42 – 6.35 (m, 1H), 3.66 (s, 3H), 3.65 (s, 3H), 3.36 (s, 3H). ¹³C{¹H} NMR (100 MHz, CDCl₃): δ (ppm) 196.7, 170.6, 162.5, 162.0, 155.8, 151.0, 146.3, 142.6, 142.0, 139.2, 136.5, 132.8, 132.5, 129.7, 128.8, 124.8, 118.9, 118.7, 117.9, 113.5, 110.3, 109.3, 70.7, 55.7, 52.1, 27.7. HRMS (ESI TOF) *m/z* calcd. For C₂₉H₂₄NO₆ [M+H]⁺ 482.16.4, found 482.1604

Methyl -5'-bromo-2-(2-hydroxybenzoyl)-1'-methyl-2'-oxo-3-phenylspiro[cyclopentane-1, 3'-indoline]-2, 4-diene-5-carboxylate (3d)

The compound **3d** was prepared following the general procedure **GP-1**.

Yellow solid (43 mg, 70%), $R_f = 0.30$ (petroleum ether/EtOAc 70:30), MP: 162-163 °C. ¹H NMR (400 MHz, CDCl₃) δ 11.39 (s, 1H), 7.83 (s, 1H), 7.40 (dd, J = 8.3, 2.0 Hz, 1H), 7.31 (dd, J = 7.5, 2.0 Hz, 2H), 7.27 – 7.12 (m, 5H), 7.03 (d, J = 1.9 Hz, 1H), 6.85 – 6.75 (m, 2H), 6.40 (s, 1H), 3.68 (s, 3H), 3.37 (s, 3H). ¹³C{¹H} NMR (100 MHz, CDCl₃): δ (ppm) 196.3, 170.6, 162.5, 161.8, 151.6, 146.6, 144.8, 142.1, 141.6, 136.6, 132.7, 132.4, 132.3, 129.9, 128.8, 128.8, 125.8, 125.8, 118.9, 118.7, 117.9, 115.0, 110.5, 70.0, 52.2, 27.7.HRMS (ESI

TOF) m/z calcd. For C₂₈H₂₁BrNO₅ [M+H]⁺ 530.0603 and 532.0583, found 530.0601 and 532.0588

Methyl -5'-chloro-2-(2-hydroxybenzoyl)-1'-methyl-2'-oxo-3-phenylspiro[cyclopentane-1, 3'-indoline]-2,4-diene-5-carboxylate (3e)

The compound **3e** was prepared following the general procedure **GP-1**.

Yellow solid (44 mg, 79%), $R_f = 0.18$ (petroleum ether/EtOAc 70:30), MP: 163-165 °C. ¹H NMR (400 MHz, CDCl₃) δ (ppm) 11.39 (s, 1H), 7.83 (s, 1H), 7.34 – 7.29 (m, 2H), 7.26 – 7.13 (m, 6H), 6.90 (d, J = 2.1 Hz, 1H), 6.86 (d, J = 8.3 Hz, 1H), 6.79 (d, J = 8.3 Hz, 1H), 6.43 – 6.36 (m, 1H), 3.68 (s, 3H), 3.37 (s, 3H). ¹³C{¹H} NMR (100 MHz, CDCl₃) δ (ppm) 196.2, 170.5, 162.4, 161.7, 151.5, 146.5, 144.2, 141.9, 141.5, 136.5, 132.5, 132.3, 129.8, 129.3, 128.7, 128.7, 127.7, 125.3, 123.0, 118.7, 118.6, 117.8, 109.8, 69.9, 52.1, 27.6. HRMS (ESI TOF) m/z calcd. For C₂₈H₂₁ClNO₅ [M+H]⁺ 486.1108, found 486.1107

Methyl - 5'-fluoro-2-(2-hydroxybenzoyl)-1'-methyl-2'-oxo-3-phenylspiro[cyclopentane-1, 3'-indoline]-2, 4-diene-5-carboxylate (3f)

The compound **3f** was prepared following the general procedure **GP-1**.

Yellow solid (44 mg, 82%), $R_f = 0.18$ (petroleum ether/EtOAc 70:30), MP: 161-163 °C. ¹H NMR (400 MHz, CDCl₃) δ 11.42 (s, 1H), 7.84 (s, 1H), 7.34 – 7.29 (m, 2H), 7.25 – 7.13 (m, 5H), 6.99 (td, J = 8.9, 2.6 Hz, 1H), 6.86 (dd, J = 8.6, 4.1 Hz, 1H), 6.83 – 6.75 (m, 1H), 6.68

(dd, J = 7.6, 2.5 Hz, 1H), 6.39 (ddd, J = 8.2, 7.3, 1.1 Hz, 1H), 3.67 (s, 3H), 3.38 (s, 3H). ¹³C {¹H} NMR (100 MHz, CDCl₃): δ (ppm) 196.3, 170.3, 162.4, 161.7, 158.8(d, $J_{(C-F)} = 241.1$ Hz), 151.3, 146.5, 141.6, 141.6, 141.5, 136.5, 132.5, 132.3, 129.8, 128.7, 128.7, 125.2, 125.1, 118.7, 118.6, 117.8, 115.6(d, $J_{(C-F)} = 23.4$ Hz), 110.8(d, $J_{(C-F)} = 25.2$ Hz), 109.4, 109.3, 70.3, 52.1, 27.6. ¹⁹F NMR (377 MHz, CDCl₃): δ (ppm) -120.4. HRMS (ESI TOF) *m/z* calcd. For C₂₈H₂₁FNO₅ [M+H]⁺ 470.1404, found 470.1406.

Methyl-2-(2-hydroxybenzoyl)-1'-methyl-5'-nitro-2'-oxo-3-phenylspiro[cyclopentane-1,3'-indoline]-2,4-diene-5-carboxylate (3g)

The compound **3g** was prepared following the general procedure **GP-1**

Yellow solid (37 mg, 65%), $R_f = 0.17$ (petroleum ether/EtOAc 70:30), MP: 218-220 °C. ¹H NMR (400 MHz, CDCl₃) δ 11.28 (s, 1H), 8.28 (dd, J = 8.7, 2.3 Hz, 1H), 7.87 (s, 1H), 7.81 (d, J = 2.3 Hz, 1H), 7.35 – 7.30 (m, 2H), 7.28 – 7.13 (m, 5H), 7.02 (d, J = 8.7 Hz, 1H), 6.80 – 6.77 (m, 1H), 6.38 (ddd, J = 8.2, 7.2, 1.1 Hz, 1H), 3.69 (d, J = 0.6 Hz, 3H), 3.47 (s, 3H). ³C {¹H} NMR (100 MHz, CDCl₃): δ (ppm) 195.8, 171.1, 162.4, 161.6, 152.4, 151.3, 147.0, 143.2, 141.4, 141.2, 136.8, 132.3, 132.1, 130.1, 128.8, 128.8, 126.7, 124.9, 118.9, 118.4, 118.3, 117.9, 108.4, 69.2, 52.2, 27.9. HRMS (ESI TOF) *m*/*z* calcd. For C₂₈H₂₁N₂O₇ [M+H]⁺ 497.1349, found 497.1350

Methyl -7'-fluoro-2-(2-hydroxybenzoyl)-1'-methyl-2'-oxo-3-phenylspiro[cyclopentane-1, 3'-indoline]-2, 4-diene-5-carboxylate (3h)

The compound **3h** was prepared following the general procedure **GP-1**.

Yellow solid (42 mg, 78%), $R_f = 0.36$ (petroleum ether/EtOAc 70:30), MP: 170-171 °C. ¹H NMR (400 MHz, CDCl₃) δ 11.44 (s, 1H), 7.83 (s, 1H), 7.33 – 7.28 (m, 2H), 7.25 – 7.12 (m, 5H), 7.00 (dd, J = 11.5, 8.4 Hz, 1H), 6.86 – 6.77 (m, 2H), 6.70 (dd, J = 7.4, 1.0 Hz, 1H), 6.37 (ddd, J = 8.2, 7.3, 1.1 Hz, 1H), 3.68 (s, 3H), 3.60 (d, J = 2.6 Hz, 3H). ¹³C{¹H} NMR(100 MHz, CDCl₃): δ (ppm) 196.5, 170.6, 162.5, 161.9, 151.3, 148.07 (d, J = 244.2 Hz), 146.5, 142.05(d, $J_{(C-F)} = 45$ Hz), 136.6, 132.7, 132.5, 132.4, 129.9, 128.8, 128.8, 126.3, 126.3, 123.1, 118.8, 118.5, 118.5, 117.9, 117.65 (d, $J_{(C-F)} = 19.4$ Hz), 70.2, 52.2, 30.06 (d, $J_{(C-F)} = 5.9$ Hz). ¹⁹F NMR (377 MHz, CDCl₃): δ (ppm) -135.0. HRMS (ESI TOF) m/z calcd. For C₂₈H₂₁FNO₅ [M+H]⁺ 470.1404, found 470.1406

Methyl -1'-allyl-2-(2-hydroxybenzoyl)-2'-oxo-3-phenylspiro[cyclopentane-1, 3'indoline]-2,4-diene-5-carboxylate (3i)

The compound 3i was prepared following the general procedure GP-1

Yellow solid (33 mg, 60%), $R_f = 0.33$ (petroleum ether/EtOAc 70:30), MP: 130-132 °C. ¹H NMR (400 MHz, CDCl₃) δ 11.47 (s, 1H), 7.86 (s, 1H), 7.36 – 7.30 (m, 2H), 7.25 – 7.15 (m, 6H), 6.94 – 6.85 (m, 3H), 6.77 (dd, J = 8.8, 1.1 Hz, 1H), 6.39 (ddd, J = 8.1, 7.3, 1.1 Hz, 1H), 6.03 – 5.88 (m, 1H), 5.51 – 5.42 (m, 1H), 5.28 (dq, J = 10.4, 1.5 Hz, 1H), 4.50 (ddt, J = 5.3, 3.6, 1.8 Hz, 2H), 3.65 (s, 3H). ¹³C NMR (100 MHz, CDCl₃): δ (ppm) 196.7, 170.5, 162.4, 161.8, 150.8, 146.3, 144.7, 142.5, 141.9, 136.4, 132.7, 132.4, 131.2, 129.6, 129.2, 128.6, 128.6, 123.3, 122.6, 122.5, 118.7, 118.6, 117.7, 117.7, 110.0, 70.2, 51.9, 43.5. HRMS (ESI TOF) m/z calcd. For C₃₀H₂₄NO₅ [M+H]⁺ 478.1654, found 478.1656

Methyl-1'-benzyl-2-(2-hydroxybenzoyl)-2'-oxo-3-phenylspiro[cyclopentane-1,3'indoline]-2,4-diene-5-carboxylate (3j)

The compound 3j was prepared following the general procedure GP-1

Red solid (24 mg, 40%), $R_f = 0.50$ (petroleum ether/EtOAc 70:30), MP: 164-166 °C. ¹H NMR (400 MHz, CDCl₃) δ 11.53 (s, 1H), 7.90 (s, 1H), 7.45 (d, J = 7.2 Hz, 2H), 7.38 – 7.31 (m, 4H), 7.30 – 7.27 (m, 1H), 7.25 – 7.12 (m, 6H), 6.93 (dd, J = 7.4, 1.0 Hz, 1H), 6.87 (td, J = 7.5, 0.9 Hz, 1H), 6.82 – 6.71 (m, 2H), 6.40 (td, J = 7.7, 1.1 Hz, 1H), 5.11 (d, J = 15.8 Hz, 1H), 5.04 (d, J = 15.8 Hz, 1H), 3.61 (s, 3H). ¹³C{¹H} NMR (100 MHz, CDCl3): δ (ppm) 197.0, 171.1, 162.6, 162.0, 150.7, 146.6, 144.8, 142.5, 142.0, 136.6, 135.8, 132.8, 132.6, 129.8, 129.4, 128.8, 128.7, 127.7, 127.6, 123.5, 122.8, 122.7, 118.9, 118.8, 117.9, 110.3, 70.4, 52.1, 45.2. HRMS (ESI TOF) *m/z* calcd. For C₃₄H₂₅NO₅ [M+H]⁺ 528.1811 found 528.1812

Methyl -2-(2-hydroxybenzoyl)-1'-methyl-2'-oxo-3-(p-tolyl)spiro[cyclopentane-1,3'indoline]-2,4-diene-5-carboxylate (3k)

The compound **3k** was prepared following the general procedure **GP-1**

Yellow solid (35 mg, 65%), $R_f = 0.21$ (petroleum ether/EtOAc 70:30), MP: 164-166 °C. ¹H NMR (400 MHz, CDCl₃) δ 11.50 (s, 1H), 7.83 (s, 1H), 7.27 (ddd, J = 7.9, 6.4, 2.5 Hz, 1H), 7.24 – 7.12 (m, 4H), 7.01 (d, J = 7.9 Hz, 2H), 6.97 – 6.84 (m, 3H), 6.81 – 6.73 (m, 1H), 6.40 (td, J = 7.7, 1.1 Hz, 1H), 3.64 (s, 3H), 3.38 (s, 3H), 2.25 (s, 3H). ¹³C{¹H} NMR (100 MHz,

CDCl₃): δ (ppm) 197.0, 171.1, 162.5, 162.0, 150.9, 146.5, 145.6, 141.7, 141.7, 140.0, 136.4, 132.5, 129.9, 129.5, 129.4, 128.7, 123.6, 122.7, 122.6, 118.9, 118.8, 117.8, 109.1, 70.4, 52.1, 27.6, 21.4. HRMS (ESI TOF) *m*/*z* calcd. For C₂₉H₂₄NO₅ [M+H]⁺ 466.1654, found 466.1654

Methyl-2-(2-hydroxybenzoyl)-3-(4-methoxyphenyl)-1'-methyl-2'-oxospiro[cyclopentane-1,3'-indoline]-2,4-diene-5-carboxylate (3l)

The compound 31 was prepared following the general procedure GP-1

Yellow solid (38 mg, 68%), $R_f = 0.12$ (petroleum ether/EtOAc 70:30), MP: 150-152 °C. ¹H NMR (400 MHz, CDCl₃) δ 11.49 (s, 1H), 7.83 (s, 1H), 7.31 – 7.26 (m, 2H), 7.25 – 7.16 (m, 3H), 6.96 – 6.86 (m, 3H), 6.78 (d, J = 8.3 Hz, 1H), 6.75 – 6.69 (m, 2H), 6.45 – 6.39 (m, 1H), 3.73 (s, 3H), 3.64 (s, 3H), 3.39 (s, 3H). ¹³C{¹H} NMR (100 MHz, CDCl₃): δ (ppm) 196.8, 171.2, 162.3, 161.9, 160.6, 150.5, 146.4, 145.5, 141.6, 140.7, 136.2, 132.4, 130.3, 129.3, 125.2, 123.6, 122.5, 118.7, 118.7, 117.7, 114.1, 108.9, 70.2, 55.3, 51.9, 27.4. HRMS (ESI TOF) m/z calcd. For C₂₉H₂₄NO₆ [M+H]⁺ 482.1604, found 482.1601

Methyl -3-(4-bromophenyl)-2-(2-hydroxybenzoyl)-1'-methyl-2'-oxospiro[cyclopentane-1,3'-indoline]-2,4-diene-5-carboxylate (3m)

The compound **3m** was prepared following the general procedure **GP-1**

Yellow solid (39 mg, 63%), $R_f = 0.21$ (petroleum ether/EtOAc 70:30), MP: 176-178 °C. ¹H NMR (400 MHz, CDCl₃) δ 11.40 (s, 1H), 7.78 (s, 1H), 7.35 (d, J = 8.4 Hz, 2H), 7.29 (dd, J = 8.0, 4.2 Hz, 1H), 7.25 – 7.14 (m, 4H), 6.95 – 6.88 (m, 3H), 6.79 (d, J = 8.3 Hz, 1H), 6.45 (t, J = 7.6 Hz, 1H), 3.65 (s, 3H), 3.38 (s, 3H). ¹³C{¹H} NMR (100 MHz, CDCl₃): δ (ppm) 196.5, 170.7, 162.6, 161.9, 149.4, 145.6, 145.6, 143.0, 142.2, 136.8, 132.3, 132.0, 131.7, 130.1, 129.6, 124.1, 123.2, 122.7, 122.7, 119.0, 118.7, 118.0, 109.2, 70.6, 52.2, 27.6. HRMS (ESI TOF) *m*/*z* calcd. For C₂₈H₂₁BrNO₅ [M+H]⁺ 530.0603 and 532.0583, found 530.0600 and 532.0587

Methyl -3-(4-chlorophenyl)-2-(2-hydroxybenzoyl)-1'-methyl-2'-oxospiro[cyclopentane-1, 3'-indoline]-2, 4-diene-5-carboxylate (3n)

The compound **3n** was prepared following the general procedure **GP-1**

Yellow solid (39 mg, 70%), $R_f = 0.18$ (petroleum ether/EtOAc 70:30), MP: 177-179 °C. ¹H NMR (400 MHz, CDCl₃) δ 11.41 (s, 1H), 7.79 (s, 1H), 7.31 – 7.22 (m, 4H), 7.22 – 7.15 (m, 3H), 6.95 – 6.86 (m, 3H), 6.82 – 6.76 (m, 1H), 6.49 – 6.39 (m, 1H), 3.65 (s, 3H), 3.38 (s, 3H). ¹³C NMR (100 MHz, CDCl₃): δ (ppm) 196.5, 170.7, 162.6, 161.9, 149.4, 145.7, 145.6, 143.0, 142.2, 136.8, 135.8, 132.3, 131.3, 129.9, 129.6, 129.1, 123.2, 122.7, 122.7, 118.9, 118.7, 118.0, 109.2, 70.6, 52.1, 27.6. HRMS (ESI TOF) *m/z* calcd. For C₂₈H₂₁ClNO₅ [M+H]⁺ 486.1108, found 486.1112

Methyl -2-(2- hydroxybenzoyl) -1' – methyl - 2'-oxo- 3-(4-(trifluoromethyl) phenyl) spiro[cyclopentane-1, 3'-indoline]-2, 4-diene-5-carboxylate (30)

The compound **30** was prepared following the general procedure **GP-1**

Yellow solid (48 mg, 80%), $R_f = 0.21$ (petroleum ether/EtOAc 70:30), MP: 170-172 °C. ¹H NMR (400 MHz, CDCl₃) δ 11.35 (s, 1H), 7.81 (s, 1H), 7.51 – 7.40 (m, 4H), 7.30 (ddd, J = 7.9, 5.6, 3.3 Hz, 1H), 7.21 (ddd, J = 8.6, 7.3, 1.7 Hz, 1H), 7.13 (dd, J = 8.0, 1.6 Hz, 1H), 6.97 – 6.90 (m, 3H), 6.79 (dd, J = 8.4, 0.8 Hz, 1H), 6.41 (ddd, J = 8.2, 7.3, 1.1 Hz, 1H), 3.66 (s, 3H), 3.39 (s, 3H). ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 196.2, 170.5, 162.5, 161.8, 149.0, 145.6, 145.3, 144.4, 142.4, 136.9, 136.3, 132.2, 131.3 (q, $J_{(C-F)} = 33$ Hz) , 129.7, 128.9, 125.75 (q, $J_{(C-F)} = 3$ Hz), 123.69 (q, $J_{(C-F)} = 271$ Hz) 122.9, 122.8, 122.3, 118.9, 118.7, 118.1, 109.3, 70.7, 52.2, 27.6. ¹⁹F NMR (377 MHz, CDCl₃): δ (ppm) -63.0. HRMS (ESI TOF) m/z calcd. For C₂₉H₂₁F₃NO₅ [M+H]⁺ 520.1372, found 520.1367

Methyl -2-(2-hydroxybenzoyl)-1'-methyl-3-(4-nitrophenyl)-2'-oxospiro[cyclopentane-1, 3'-indoline]-2, 4-diene-5-carboxylate (3p)

The compound **3p** was prepared following the general procedure **GP-1**

Yellow solid (37 mg, 65%), $R_f = 0.12$ (petroleum ether/EtOAc 70:30), MP: 170-172 °C. ¹H NMR (400 MHz, CDCl₃) δ 11.32 (s, 1H), 8.15 – 8.04 (m, 2H), 7.82 (d, J = 2.0 Hz, 1H), 7.55 – 7.46 (m, 2H), 7.31 (dq, J = 8.1, 4.0, 3.5 Hz, 1H), 7.26 – 7.19 (m, 1H), 7.13 (d, J = 8.0 Hz, 1H), 7.02 – 6.89 (m, 3H), 6.81 (d, J = 8.4 Hz, 1H), 6.48 – 6.38 (m, 1H), 3.67 (s, 3H), 3.39 (s, 3H). ¹³C{¹H} NMR (100 MHz, CDCl₃): δ (ppm) 195.8, 170.0, 162.5, 161.5, 147.9, 147.8, 145.4, 145.3, 144.6, 142.5, 138.9, 137.1, 131.8, 129.7, 129.4, 123.9, 122.7, 122.5, 118.9, 118.5, 118.2, 109.3, 70.9, 52.1, 27.6. HRMS (ESI TOF) *m*/*z* calcd. For C₂₈H₂₁N₂O₇ [M+H]⁺ 497.1349, found 497.1355

Methyl -3-(4-cyanophenyl)-2-(2-hydroxybenzoyl)-1'-methyl-2'-oxospiro [cyclopentane-1, 3'-indoline]-2, 4-diene-5-carboxylate (3q)

The compound 3q was prepared following the general procedure GP-1

Yellow solid (41 mg, 74%), $R_f = 0.10$ (petroleum ether/EtOAc 70:30), MP: 226-228 °C. ¹H NMR (400 MHz, CDCl₃) δ 11.31 (s, 1H), 7.79 (s, 1H), 7.54 – 7.48 (m, 2H), 7.45 – 7.40 (m, 2H), 7.30 (ddd, J = 8.0, 5.1, 3.9 Hz, 1H), 7.26 – 7.21 (m, 1H), 7.11 (dd, J = 8.0, 1.5 Hz, 1H), 6.96 – 6.90 (m, 3H), 6.83 – 6.78 (m, 1H), 6.46 – 6.39 (m, 1H), 3.66 (s, 3H), 3.38 (s, 3H). ¹³C {¹H} NMR (100 MHz, CDCl₃): δ (ppm) 195.8, 170.1, 162.5, 161.6, 148.4, 145.4, 144.9, 144.7, 142.5, 137.1, 137.0, 132.4, 131.9, 129.7, 129.0, 122.7, 122.7, 122.6, 118.9, 118.5, 118.1, 118.0, 113.1, 109.2, 70.7, 52.1, 27.5. HRMS (ESI TOF) *m*/*z* calcd. For C₂₉H₂₁N₂O₅ [M+H]⁺ 477.1450, found 477.1454

Methyl -3-(3-fluorophenyl)-2-(2-hydroxybenzoyl)-1'-methyl-2'-oxospiro[cyclopentane-1,3'-indoline]-2,4-diene-5-carboxylate (3r)

The compound **3r** was prepared following the general procedure **GP-1**

Yellow solid (44 mg, 81%), $R_f = 0.21$ (petroleum ether/EtOAc 70:30), MP: 222-223 °C. ¹H NMR (400 MHz, CDCl₃) δ 11.40 (s, 1H), 7.79 (s, 1H), 7.32 – 7.27 (m, 1H), 7.26 – 7.12 (m, 3H), 7.10 – 7.02 (m, 2H), 6.97 – 6.89 (m, 4H), 6.81 – 6.76 (m, 1H), 6.44 (ddd, J = 8.2, 7.3, 1.1 Hz, 1H), 3.65 (s, 3H), 3.38 (s, 3H). ¹³C{¹H} NMR (100 MHz, CDCl₃): δ (ppm) 196.3, 170.5, 162.6 (d, $J_{(C-F)} = 246$ Hz), 162.4, 161.7, 149.2, 149.2, 145.5, 145.5, 143.4, 142.0,

136.6, 134.8, 134.7, 132.1, 130.4, 130.3, 129.5, 124.6, 124.6, 123.0, 122.6, 122.6, 118.7, 118.7, 117.9, 116.54 (d, $J_{(C-F)} = 21.1$ Hz), 115.19 (d, $J_{(C-F)} = 22.6$ Hz), 109.1, 70.5, 52.0, 27.5 ¹⁹F NMR (377 MHz, CDCl₃): δ (ppm) -111.8. HRMS (ESI TOF) m/z calcd. C₂₈H₂₁FNO₅ [M+H]⁺ 470.1404, found 470.1407

Methyl -3-(2-fluorophenyl)-2-(2-hydroxybenzoyl)-1'-methyl-2'-oxospiro[cyclopentane-1,3'-indoline]-2,4-diene-5-carboxylate (3s)

The compound 3s was prepared following the general procedure GP-1

Yellow solid (40 mg, 74%), $R_f = 0.21$ (petroleum ether/EtOAc 70:30), MP: 166-168 °C. ¹H NMR (400 MHz, CDCl₃) δ 11.27 (s, 1H), 7.79 (d, J = 2.4 Hz, 1H), 7.32 – 7.26 (m, 1H), 7.19 (dddd, J = 13.8, 8.8, 6.9, 3.5 Hz, 4H), 7.02 – 6.88 (m, 5H), 6.78 – 6.73 (m, 1H), 6.41 (ddd, J = 8.3, 7.4, 1.1 Hz, 1H), 3.65 (s, 3H), 3.41 (s, 3H). ¹³C{¹H} NMR (100 MHz, CDCl₃): δ (ppm) 195.8, 170.8, 162.2, 161.9, 159.9 (d, $J_{(C-F)} = 250.1$ Hz), 146.44 (d, $J_{(C-F)} = 2.8$ Hz), 145.9, 145.7, 145.1, 141.8, 131.9, 131.8, 131.7, 131.0 (d, $J_{(C-F)} = 2.8$ Hz),, 129.6, 124.5 (d, $J_{(C-F)} = 3.6$ Hz), 123.3, 122.7 (d, $J_{(C-F)} = 5.7$ Hz), 121.4, 121.3, 119.0, 118.6, 117.9, 116.1 (d, $J_{(C-F)} = 21.6$ Hz), 109.2, 69.9, 52.1, 27.6. ¹⁹F NMR (377MHz, CDCl₃): δ (ppm) -112.0. HRMS (ESI TOF) m/z calcd. C₂₈H₂₁FNO₅ [M+H]⁺ 470.1404, found 470.1407

Methyl-2-(2-hydroxybenzoyl)-3-(2-methoxyphenyl)-1'-methyl-2'-oxospiro[cyclopentane-1,3'-indoline]-2,4-diene-5-carboxylate (3t)

The compound **3t** was prepared following the general procedure **GP-1**

Yellow solid (32 mg, 58%), $R_f = 0.12$ (petroleum ether/EtOAc 70:30), MP: 180-182 °C. ¹H NMR (400 MHz, CDCl₃) δ 11.39 (s, 1H), 7.79 (s, 1H), 7.29 – 7.26 (m, 1H), 7.25 (dd, J = 3.3, 1.5 Hz, 1H), 7.21 – 7.10 (m, 3H), 6.93 (dd, J = 7.6, 1.1 Hz, 2H), 6.89 (td, J = 7.3, 1.0 Hz, 1H), 6.82 (td, J = 7.5, 1.0 Hz, 1H), 6.73 (dd, J = 8.4, 0.8 Hz, 1H), 6.65 (d, J = 7.8 Hz, 1H), 6.35 (ddd, J = 8.2, 7.3, 1.1 Hz, 1H), 3.66 (s, 3H), 3.63 (s, 3H), 3.41 (s, 3H). ¹³C{¹H} NMR (100 MHz, CDCl₃): δ (ppm) 196.0, 171.5, 162.1, 161.7, 156.6, 148.1, 147.9, 145.7, 143.5, 141.1, 135.8, 131.9, 131.3, 130.3, 129.3, 124.0, 122.6, 122.5, 122.5, 120.8, 119.4, 118.3, 117.4, 110.9, 109.0, 69.6, 55.1, 52.0, 27.6. HRMS (ESI TOF) *m*/*z* calcd. For C₂₉H₂₄NO₆ [M+H]⁺ 482.1604 found 482.1604

Methyl -3-(2-bromophenyl)-2-(2-hydroxybenzoyl)-1'-methyl-2'-oxospiro[cyclopentane-1,3'-indoline]-2,4-diene-5-carboxylate (3u)

The compound **3u** was prepared following the general procedure **GP-1**

Yellow solid (37 mg, 61%), $R_f = 0.26$ (petroleum ether/EtOAc 70:30), MP: 181-183 °C. ¹H NMR (400 MHz, CDCl₃) δ 11.14 (s, 1H), 7.79 (s, 1H), 7.56 – 7.52 (m, 1H), 7.34 – 7.26 (m, 2H), 7.17 – 7.03 (m, 4H), 7.01 – 6.88 (m, 3H), 6.70 (dd, J = 8.4, 0.8 Hz, 1H), 6.46 (ddd, J = 8.2, 7.3, 1.1 Hz, 1H), 3.65 (s, 3H), 3.43 (s, 3H). ¹³C{¹H} NMR (100 MHz, CDCl₃): δ (ppm) 195.3, 171.0, 162.0, 161.9, 151.7, 147.0, 145.8, 145.7, 140.8, 136.4, 134.6, 133.1, 132.1, 132.0, 130.9, 129.6, 127.8, 123.3, 122.7, 122.6, 122.1, 119.4, 118.5, 117.7, 109.2, 69.3, 52.1, 27.6. HRMS (ESI TOF) *m*/*z* calcd. For C₂₈H₂₁BrNO₅ [M+H]⁺ 530.0603 and 532.0583, found 530.0599 and 532.0583 Methyl -3-(2-chlorophenyl)-2-(2-hydroxybenzoyl)-1'-methyl-2'-oxospiro[cyclopentane-1,3'-indoline]-2,4-diene-5-carboxylate (3v)

The compound **3v** was prepared following the general procedure **GP-1** Yellow solid (40 mg, 72%), $R_f = 0.26$ (petroleum ether/EtOAc 70:30), MP: 183-185 °C. ¹H NMR (400 MHz, CDCl₃) δ 11.17 (s, 1H), 7.78 (s, 1H), 7.34 (dd, J = 8.0, 0.9 Hz, 1H), 7.29 (td, J = 7.7, 1.4 Hz, 1H), 7.26 – 7.23 (m, 1H), 7.18 – 7.09 (m, 3H), 7.03 – 6.89 (m, 4H), 6.70 (dd, J = 8.4, 0.8 Hz, 1H), 6.44 (ddd, J = 8.2, 7.3, 1.1 Hz, 1H), 3.65 (s, 3H), 3.43 (s, 3H). ¹³C{¹H} NMR (100 MHz, CDCl₃): δ (ppm) 195.3, 171.0, 162.0, 161.9, 150.3, 146.9, 146.0, 145.7, 141.1, 136.4, 132.6, 132.5, 131.9, 131.7, 130.8, 129.9, 129.6, 127.2, 123.2, 122.7, 122.6, 119.4, 118.5, 117.7, 109.2, 69.4, 52.1, 27.6. HRMS (ESI TOF) *m/z* calcd. For C₂₈H₂₁CINO₅ [M+H]⁺ 486.1108, found 486.1104

Methyl -2-(2-hydroxybenzoyl)-1'-methyl-3-(2-nitrophenyl)-2'-oxospiro[cyclopentane-1,3'-indoline]-2,4-diene-5-carboxylate) (3w)

The compound 3w was prepared following the general procedure GP-1

Yellow solid (30 mg, 53%), $R_f = 0.11$ (petroleum ether/EtOAc 70:30), MP: 195-197 °C.¹H NMR (400 MHz, CDCl₃) δ 11.07 (s, 1H), 8.15 – 8.08 (m, 1H), 7.47 (dd, J = 8.0, 1.5 Hz, 1H), 7.44 – 7.35 (m, 3H), 7.30 (td, J = 7.8, 1.2 Hz, 1H), 7.23 – 7.18 (m, 1H), 7.17 – 7.09 (m, 2H), 6.98 – 6.91 (m, 2H), 6.69 (dd, J = 8.4, 0.8 Hz, 1H), 6.40 (ddd, J = 8.2, 7.3, 1.1 Hz, 1H), 3.64 (s, 3H), 3.44 (s, 3H). ¹³C{¹H} NMR (100 MHz, CDCl₃): δ (ppm) 195.0, 171.1, 162.0, 161.8, 149.8, 146.9, 145.6, 145.2, 145.1, 141.3, 136.6, 134.2, 133.1, 131.5, 130.6, 129.7, 129.6,

125.3, 123.0, 122.9, 122.9, 119.8, 118.9, 117.9, 109.3, 69.4, 52.1, 27.6. HRMS (ESI TOF) *m/z* calcd. For C₂₈H₂₁N₂O₇ [M+H]⁺ 497.1349, found 497.1347

Methyl -3-(3, 4-dimethoxyphenyl)-2-(2-hydroxybenzoyl)-1'-methyl-2'-oxospiro [cyclopentane-1, 3'-indoline]-2, 4-diene-5-carboxylate (3x)

The compound 3x was prepared following the general procedure GP-1

Yellow solid (32 mg, 54%), $R_f = 0.06$ (petroleum ether/EtOAc 70:30), MP: 170-172 °C. ¹H NMR (400 MHz, CDCl₃) δ 11.45 (s, 1H), 7.85 (s, 1H), 7.30 – 7.28 (m, 1H), 7.24 – 7.19 (m, 2H), 7.04 (dd, J = 8.3, 2.1 Hz, 1H), 6.94 – 6.90 (m, 3H), 6.80 – 6.75 (m, 2H), 6.64 (d, J = 2.0 Hz, 1H), 6.45 – 6.41 (m, 1H), 3.83 (s, 3H), 3.65 (s, 3H), 3.58 (s, 3H), 3.40 (s, 3H).¹³C{¹H} NMR (100 MHz, CDCl₃): δ (ppm) 197.1, 171.3, 162.3, 162.0, 150.4, 148.8, 146.3, 145.6, 141.8, 140.8, 136.6, 132.4, 129.5, 125.4, 123.8, 122.7, 121.6, 119.2, 119.0, 117.8, 112.3, 111.0, 109.1, 70.3, 56.0, 55.8, 52.1, 27.6. HRMS (ESI TOF) *m/z* calcd. For C₃₀H₂₆NO₇ [M+H]⁺ 512.1709, found 512.1707

Methyl-3-(3, 5-dibromophenyl)-2-(2-hydroxybenzoyl)-1'-methyl-2'-oxospiro [cyclopentane-1, 3'-indoline]-2, 4-diene-5-carboxylate (3y)

The compound **3y** was prepared following the general procedure **GP-1**

Yellow solid (42 mg, 60%), $R_f = 0.30$ (petroleum ether/EtOAc 70:30), MP: 167-169 °C. ¹H NMR (400 MHz, CDCl₃) δ 11.19 (s, 1H), 7.74 (s, 1H), 7.51 (t, J = 1.7 Hz, 1H), 7.39 (d, J = 1.7 Hz, 2H), 7.33 – 7.26 (m, 2H), 7.13 (dd, J = 8.1, 1.7 Hz, 1H), 7.00 – 6.88 (m, 3H), 6.84 (dd, J = 8.4, 1.0 Hz, 1H), 6.50 (ddd, J = 8.2, 7.2, 1.1 Hz, 1H), 3.66 (s, 3H), 3.39 (s, 3H). ¹³C {¹H} NMR(100 MHz, CDCl₃): δ (ppm) 195.5, 170.3, 162.4, 161.6, 147.7, 145.5, 144.7, 144.7, 142.5, 136.9, 135.9, 134.8, 131.6, 130.2, 129.6, 123.1, 122.7, 122.6, 118.8, 118.5, 118.1, 109.2, 70.6, 52.1, 27.5. HRMS (ESI TOF) *m*/*z* calcd. For C₂₈H₂₀Br₂NO₅ [M+H]⁺ 607.9708, 609.9688 found 607.9706; 609.9689 and 611.9671

Methyl-3- (3, 5-dichlorophenyl)-2-(2-hydroxybenzoyl)-1'-methyl- 2'-oxospiro [cyclopentane-1, 3'-indoline]-2,4-diene-5-carboxylate (3z)

The compound 3z was prepared following the general procedure GP-1

Yellow solid (38 mg, 64%), $R_f = 0.30$ (petroleum ether/EtOAc 70:30), MP: 173-175 °C. ¹H NMR (400 MHz, CDCl₃) δ 11.06 (s, 1H), 7.72 (s, 1H), 7.35 – 7.26 (m, 1H), 7.29 – 7.07 (m, 5H), 7.00 – 6.88 (m, 3H), 6.80 – 6.73 (m, 1H), 6.52 – 6.43 (m, 1H), 3.65 (s, 3H), 3.43 (s, 3H). ¹³C{¹H} NMR (100 MHz, CDCl₃): δ (ppm) 194.9, 170.7, 162.1, 161.8, 148.6, 146.7, 146.1, 145.7, 141.6, 136.6, 134.0, 133.2, 131.6, 131.2, 131.0, 130.9, 130.7, 129.7, 123.0, 122.8, 122.6, 119.3, 118.6, 118.0, 109.3, 69.6, 52.2, 27.7. HRMS (ESI TOF) *m/z* calcd. For C₂₈H₂₀Cl₂NO₅ [M+H]⁺ 520.0719, found 520.0720

Methyl-3-(furan-2-yl)-2-(2-hydroxybenzoyl)-1'-methyl-2'-oxospiro[cyclopentane-1,3'indoline]-2, 4-diene-5-carboxylate (3ar)

The compound **3ar** was prepared following the general procedure **GP-1**

Yellow solid (26 mg, 51%), $R_f = 0.21$ (petroleum ether/EtOAc 70:30), MP: 149-151 °C. ¹H NMR (400 MHz, CDCl₃) δ 11.49 (s, 1H), 7.84 (s, 1H), 7.45 (dd, J = 8.0, 1.4 Hz, 1H), 7.34 (ddd, J = 8.6, 7.3, 1.6 Hz, 1H), 7.30 – 7.26 (m, 1H), 7.21 (dd, J = 1.8, 0.6 Hz, 1H), 6.89 (ddd, J = 6.5, 5.7, 2.1 Hz, 4H), 6.69 – 6.62 (m, 1H), 6.52 (dd, J = 3.5, 0.6 Hz, 1H), 6.35 (dd, J = 3.5, 1.8 Hz, 1H), 3.64 (s, 3H), 3.34 (s, 3H). ¹³C{¹H} NMR (100 MHz, CDCl₃): δ (ppm) 196.7, 171.0, 162.3, 161.9, 147.3, 145.5, 144.8, 143.4, 141.5, 137.8, 137.5, 136.6, 132.4, 129.5, 123.7, 123.0, 122.7, 120.0, 119.0, 118.1, 113.8, 112.2, 109.1, 70.3, 52.1, 27.6. HRMS (ESI TOF) *m/z* calcd. For C₂₃H₂₀N₃O₅ [M+H]⁺ 442.1291, found 442.1299

Methyl -2-(2-hydroxybenzoyl)-1'-methyl-2'-oxo-3-(thiophen-2-yl)spiro[cyclopentane-1,3'-indoline]-2,4-diene-5-carboxylate (3as)

The compound 3as was prepared following the general procedure GP-1

Yellow solid (27 mg, 50%), $R_f = 0.23$ (petroleum ether/EtOAc 70:30), MP: 157-159 °C. ¹H NMR (400 MHz, CDCl₃) δ 11.48 (s, 1H), 7.82 (s, 1H), 7.46 (dd, J = 8.0, 1.4 Hz, 1H), 7.34 – 7.26 (m, 3H), 7.09 (dd, J = 3.7, 1.1 Hz, 1H), 6.97 – 6.83 (m, 5H), 6.64 – 6.56 (m, 1H), 3.65 (s, 3H), 3.35 (s, 3H). ¹³C{¹H} NMR (100 MHz, CDCl₃): δ (ppm) 196.8, 170.9, 162.6, 161.9, 145.7, 145.4, 142.0, 141.4, 139.7, 136.9, 134.8, 132.5, 130.1, 129.6, 129.2, 128.0, 123.5, 123.0, 122.7, 119.3, 119.3, 118.1, 109.1, 70.5, 52.1, 27.5. HRMS (ESI TOF) *m*/*z* calcd. For C₂₆H₂₀NO₅S [M+H]⁺ 458.1062, found 458.1060

Methyl-5'-(2-methoxyphenyl)-1''-methyl-2'',3-dioxo-3*H*-dispiro[benzofuran-2,1'cyclopentane-2', 3''-indolin]-3'-ene-3'-carboxylate (3t')

The compound **3t'** was prepared following the general procedure **GP-2**

White solid (23 mg, 42%), $R_f = 0.15$ (petroleum ether/EtOAc 70:30), MP: 206-208 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.55 (dd, J = 7.5, 1.7 Hz, 1H), 7.47 (ddd, J = 7.7, 1.4, 0.6 Hz, 1H), 7.44 (d, J = 2.6 Hz, 1H), 7.38 (ddd, J = 8.6, 7.2, 1.5 Hz, 1H), 7.30 (dd, J = 7.5, 0.8 Hz, 1H), 7.25 – 7.14 (m, 2H), 6.99 (dtd, J = 20.6, 7.6, 1.0 Hz, 2H), 6.93 – 6.86 (m, 1H), 6.80 (d, J = 8.4 Hz, 1H), 6.67 – 6.58 (m, 2H), 5.02 (d, J = 2.5 Hz, 1H), 3.60 (s, 3H), 3.09 (s, 3H), 3.09 (s, 3H). ¹³C{¹H} NMR (100 MHz, CDCl₃): δ (ppm) 200.0, 173.7, 171.8, 162.5, 157.1, 147.7, 144.7, 137.7, 136.5, 130.2, 129.2, 129.2, 126.5, 125.6, 124.3, 122.3, 121.9, 120.4, 112.8, 109.2, 107.9, 95.2, 65.3, 54.2, 52.4, 52.0, 26.9. HRMS (ESI TOF) m/z calcd. For C₂₉H₂₄NO₆ [M+H]⁺ 482.1604 found 482.1600

Methyl -5'-(2-bromophenyl)-1''-methyl-2'',3-dioxo-3*H*-dispiro[benzofuran-2,1'cyclopentane-2',3''-indolin]-3'-ene-3'-carboxylate (3u')

The compound **3u'** was prepared following the general procedure **GP-2** Brown solid (22 mg, 36%), $R_f = 0.18$ (petroleum ether/EtOAc 70:30), MP: 192-194 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.89 (dd, J = 8.0, 1.7 Hz, 1H), 7.45 – 7.35 (m, 4H), 7.33 – 7.30 (m, 1H), 7.24 – 7.20 (m, 1H), 7.15 (tdd, J = 7.7, 2.3, 1.5 Hz, 2H), 6.98 – 6.86 (m, 2H), 6.85 – 6.80 (m, 1H), 6.61 (d, J = 7.8 Hz, 1H), 5.15 (d, J = 2.7 Hz, 1H), 3.60 (s, 3H), 3.11 (s, 3H). ¹³C{¹H} NMR (100 MHz, CDCl₃): δ (ppm) 200.2, 174.0, 172.0, 162.4, 147.6, 144.7, 138.1, 136.7, 135.5, 132.4, 132.2, 129.7, 129.3, 127.2, 126.4, 126.1, 125.3, 124.4, 122.5, 122.5, 120.3, 113.0, 107.9, 94.9, 65.4, 56.5, 52.1, 26.9. HRMS (ESI TOF) *m/z* calcd. For C₂₈H₂₁BrNO₅ [M+H]⁺ 530.0603 and 532.0583, found 530.0608 and 532.0590 Methyl-5'-(2-chlorophenyl)-1''-methyl-2'',3-dioxo-3*H*-dispiro[benzofuran-2,1'cyclopentane-2',3''-indolin]-3'-ene-3'-carboxylate (3v')

The compound **3v'** was prepared following the general procedure **GP-2** White solid (30 mg, 54%), $R_f = 0.12$ (petroleum ether/EtOAc 70:30), MP: 273-275 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.90 – 7.80 (m, 1H), 7.43 – 7.34 (m, 3H), 7.33 (d, J = 2.7 Hz, 1H), 7.26 – 7.20 (m, 3H), 7.16 (td, J = 7.7, 1.2 Hz, 1H), 6.99 – 6.87 (m, 2H), 6.85 – 6.79 (m, 1H), 6.62 (d, J = 7.7 Hz, 1H), 5.15 (d, J = 2.6 Hz, 1H), 3.61 (s, 3H), 3.10 (s, 3H). ¹³C{¹H} NMR (100 MHz, CDCl₃): δ (ppm) 200.0, 173.9, 171.9, 162.4, 147.3, 144.7, 138.1, 136.9, 135.1, 133.7, 132.1, 129.4, 129.3, 128.9, 126.7, 126.4, 125.3, 124.4, 122.5, 122.5, 120.1, 112.9, 108.0, 95.0, 65.4, 54.1, 52.1, 26.9. HRMS (ESI TOF) *m/z* calcd. For C₂₈H₂₁CINO₅ [M+H]⁺ 486.1108, found 486.1119

Methyl-5'-hydroxy-1''-methyl-2'', 3-dioxo-3'-phenyl-3*H*-dispiro[benzo[*b*]thiophene-2, 2'-cyclopentane-1',3''-indolin]-3'-ene-5'-carboxylate (4a)

The compound 4a was prepared following the general procedure GP-3

Yellow solid (31 mg, 56%), dr >20:1. $R_f = 0.34$ (petroleum ether/EtOAc 60:40), MP: 219-221 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.74 (d, J = 7.7 Hz, 1H), 7.42 – 7.35 (m, 1H), 7.23 – 7.18 (m, 3H), 7.17 – 7.11 (m, 3H), 7.10 – 7.04 (m, 3H), 6.94 (s, 1H), 6.81 (t, J = 7.6 Hz, 1H), 6.71 (d, J = 7.8 Hz, 1H), 5.10 (s, 1H), 3.60 (s, 2H), 3.13 (s, 2H). ¹³C{¹H} NMR (100 MHz, CDCl₃): δ (ppm) 202.8, 175.5, 169.2, 154.3, 148.5, 145.5, 137.3, 135.5, 133.4, 129.5, 129.4,

129.1, 128.5, 128.0, 127.5, 127.0, 125.5, 124.2, 122.8, 122.6, 108.1, 87.4, 77.7, 64.7, 52.8, 26.5. HRMS (ESI TOF) *m*/*z* calcd. For C₂₈H₂₁NO₅SNa [M+Na]⁺ 506.1038, found 506.1037

Methyl-5'-hydroxy-1'',5''-dimethyl-2'',3-dioxo-3'-phenyl-3*H*-dispiro[benzo[*b*]thiophene-2,2'-cyclopentane-1',3''-indolin]-3'-ene-5'-carboxylate (4b)

The compound 4b was prepared following the general procedure GP-3

Yellow solid (28mg, 49%), dr >20:1, $R_f = 0.33$ (petroleum ether/EtOAc 60:40), MP: 257-259 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.74 (d, J = 7.8 Hz, 1H), 7.38 (t, J = 7.6 Hz, 1H), 7.23 – 7.13 (m, 3H), 7.13 – 7.04 (m, 4H), 7.02 (s, 1H), 6.93 (d, J = 4.9 Hz, 2H), 6.59 (d, J = 7.9 Hz, 1H), 5.07 (s, 1H), 3.60 (s, 3H), 3.10 (s, 3H), 2.12 (s, 3H). ¹³C{¹H} NMR (100 MHz, CDCl₃): δ (ppm) 202.9, 175.3, 169.2, 154.4, 148.4, 143.1, 137.2, 135.5, 133.4, 131.9, 129.8, 129.5, 129.0, 128.5, 128.3, 127.8, 126.9, 125.4, 124.2, 122.7, 107.8, 87.3, 77.8, 64.8, 52.8, 26.5, 21.4. HRMS (ESI TOF) *m/z* calcd. For C₂₉H₂₄NO₅S [M+H]⁺ 498.1375, found 498.1377

Methyl-5'-hydroxy-5''-methoxy-1''-methyl-2'',3-dioxo-3'-phenyl-*3H*dispiro[benzo[*b*]thiophene-2,2'-cyclopentane-1',3''-indolin]-3'-ene-5'-carboxylate (4c)

The compound 4c was prepared following the general procedure GP-3

Yellow solid (30 mg, 51%), dr >20:1, $R_f = 0.21$ (petroleum ether/EtOAc 60:40), MP: 249-251 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.82 (ddd, J = 7.8, 1.3, 0.7 Hz, 1H), 7.46 (ddd, J = 7.9, 7.3, 1.4 Hz, 1H), 7.29 – 7.26 (m, 1H), 7.25 – 7.11 (m, 6H), 7.00 (s, 1H), 6.92 (d, J = 2.5 Hz, 1H), 6.75 (dd, J = 8.5, 2.5 Hz, 1H), 6.68 (d, J = 8.5 Hz, 1H), 5.15 (s, 1H), 3.68 (s, 3H), 3.68 (s, 3H), 3.17 (s, 3H). ¹³C{¹H} NMR (100 MHz, CDCl₃): δ (ppm) 202.9, 175.1, 169.1, 155.5, 154.4, 148.5, 139.0, 137.3, 135.4, 133.4, 129.5, 129.1, 128.5, 127.9, 126.9, 126.9, 126.9, 125.6, 124.3, 123.9, 114.9, 114.3, 108.3, 87.3, 77.7, 64.9, 55.8, 52.8, 26.6. HRMS (ESI TOF) m/z calcd. For C₂₉H₂₃NO₆SNa [M+Na]⁺ 536.1144, found 536.1143

Methyl-5''-bromo-5'-hydroxy-1''-methyl-2'',3-dioxo-3'-phenyl-3*H*dispiro[benzo[*b*]thiophene-2,2'-cyclopentane-1',3''-indolin]-3'-ene-5'-carboxylate (4d)

The compound 4d was prepared following the general procedure GP-3

Yellow solid (28 mg, 43%), dr >20:1, $R_f = 0.33$ (petroleum ether/EtOAc 60:40), MP: 230-232 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.86 (d, J = 7.8 Hz, 1H), 7.49 (t, J = 7.6 Hz, 1H), 7.38 (d, J = 1.7 Hz, 1H), 7.34 (dd, J = 8.3, 1.9 Hz, 1H), 7.24 – 7.08 (m, 7H), 6.99 (s, 1H), 6.66 (d, J = 8.3 Hz, 1H), 5.07 (s, 1H), 3.70 (s, 3H), 3.18 (s, 3H). ¹³C{¹H} NMR (100 MHz, CDCl₃): δ (ppm) 202.5, 175.1, 169.1, 154.0, 148.4, 144.6, 137.5, 135.2, 133.2, 132.4, 130.6, 129.3, 129.2, 128.5, 128.1, 126.9, 125.8, 124.9, 124.2, 115.2, 109.5, 87.5, 77.6, 64.5, 53.0, 26.6. HRMS (ESI TOF) *m*/*z* calcd. For C₂₈H₂₀BrNO₅SNa [M+Na]⁺ 584.0143, found 584.0150

Methyl-5''-chloro-5'-hydroxy-1''-methyl-2'',3-dioxo-3'-phenyl-3*H*dispiro[benzo[*b*]thiophene-2,2'-cyclopentane-1',3''-indolin]-3'-ene-5'-carboxylate (4e)

The compound 4e was prepared following the general procedure GP-3

Yellow solid (25 mg, 42%), dr >20:1, $R_f = 0.3$ (petroleum ether/EtOAc 60:40), MP: 236-238 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.81 – 7.75 (m, 1H), 7.47 – 7.38 (m, 1H), 7.19 (d, J = 2.7 Hz, 2H), 7.17 – 7.08 (m, 5H), 7.07 – 7.03 (m, 2H), 6.92 (s, 1H), 6.63 (d, J = 8.3 Hz, 1H), 5.04 (s, 1H), 3.63 (s, 3H), 3.11 (s, 3H). ¹³C{¹H} NMR (100 MHz, CDCl₃): δ (ppm) 202.5, 175.2, 169.1, 154.0, 148.5, 144.1, 137.5, 135.2, 133.1, 129.5, 129.3, 129.2, 128.5, 128.1, 127.9, 127.9, 126.9, 126.9, 125.8, 124.5, 124.2, 109.0, 87.5, 77.5, 64.6, 53.0, 26.7. HRMS (ESI TOF) *m*/*z* calcd. For C₂₈H₂₁CINO₅S [M+H]⁺ 518.0829, found 518.0823

Methyl-5''-fluoro-5'-hydroxy-1''-methyl-2'',3-dioxo-3'-phenyl-3*H*dispiro[benzo[*b*]thiophene-2,2'-cyclopentane-1',3''-indolin]-3'-ene-5'-carboxylate (4f)

The compound 4f was prepared following the general procedure GP-3

Yellow solid (26 mg, 45%), dr >20:1, $R_f = 0.3$ (petroleum ether/EtOAc 60:40), MP: 184-186 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.80 – 7.75 (m, 1H), 7.42 (td, J = 8.0, 1.4 Hz, 1H), 7.23 – 7.19 (m, 1H), 7.17 – 7.07 (m, 4H), 7.05 (dd, J = 7.2, 1.6 Hz, 2H), 6.99 (dd, J = 8.9, 2.6 Hz, 1H), 6.92 (s, 1H), 6.86 (td, J = 8.7, 2.6 Hz, 1H), 6.63 (dd, J = 8.5, 4.3 Hz, 1H), 5.06 (s, 1H), 3.62 (s, 3H), 3.12 (s, 3H). ¹³C{¹H} NMR (100 MHz, CDCl₃): δ (ppm) 202.6, 175.3, 169.1,
158.81 (d, $J_{(C-F)} = 239.7$ Hz), 154.2, 148.6, 141.5, 137.5, 135.2, 133.2, 129.3, 129.2, 128.5, 128.2, 126.9, 125.7, 124.4, 124.3, 124.2, 115.9 (d, $J_{(C-F)} = 26$ Hz), 115.8(d, $J_{(C-F)} = 23$ Hz), 108.40 (d, $J_{(C-F)} = 8.2$ Hz), 87.4, 77.6, 64.7, 52.9, 26.7. ¹⁹F NMR (377 MHz, CDCl₃): δ (ppm) -120.3. HRMS (ESI TOF) m/z calcd. For C₂₈H₂₀FNO₅SNa [M+Na]⁺ 524.0944, found 524.0941

Methyl-5'-hydroxy-1''-methyl-5''-nitro-2'',3-dioxo-3'-phenyl-3*H*dispiro[benzo[*b*]thiophene-2,2'-cyclopentane-1',3''-indolin]-3'-ene-5'-carboxylate (4g)



The compound 4g was prepared following the general procedure GP-3

Yellow solid (25mg, 41%), dr >20:1, $R_f = 0.23$ (petroleum ether/EtOAc 60:40), MP: 227-229 °C. ¹H NMR (400 MHz, CDCl₃) δ 8.21 (dd, J = 8.6, 2.2 Hz, 1H), 8.16 (d, J = 2.2 Hz, 1H), 7.87 (d, J = 7.8 Hz, 1H), 7.48 (q, J = 6.7, 5.5 Hz, 1H), 7.30 (t, J = 7.3 Hz, 1H), 7.25 – 7.10 (m, 6H), 7.00 (s, 1H), 6.87 (d, J = 8.7 Hz, 1H), 5.18 (s, 1H), 3.72 (s, 3H), 3.27 (s, 3H). ¹³C {¹H} NMR(100 MHz, CDCl₃): δ (ppm) 202.1, 175.9, 169.1, 153.5, 151.2, 148.5, 143.2, 141.7, 137.7, 134.8, 132.8, 129.3, 129.0, 128.6, 128.4, 126.8, 126.7, 126.1, 124.2, 123.7, 123.2, 107.7, 87.9, 64.1, 53.1, 26.9. HRMS (ESI TOF) *m*/*z* calcd. For C₂₈H₂₀N₂O₇S [M+H]⁺ 529.1069, found 529.1076

Methyl-7''-fluoro-5'-hydroxy-1''-methyl-2'',3-dioxo-3'-phenyl-3*H*dispiro[benzo[*b*]thiophene-2, 2'-cyclopentane-1', 3''-indolin]-3'-ene-5'-carboxylate (4h)



The compound 4h was prepared following the general procedure GP-3

Yellow solid (29 mg, 50%), dr >20:1, $R_f = 0.5$ (petroleum ether/EtOAc 60:40), MP: 188-190 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.80 (d, J = 7.4 Hz, 1H), 7.49 (t, J = 7.6 Hz, 1H), 7.30 – 7.26 (m, 1H), 7.20 (dt, J = 14.8, 7.4 Hz, 4H), 7.10 (dd, J = 18.6, 7.5 Hz, 3H), 7.00 (s, 1H), 6.95 (dd, J = 11.4, 8.5 Hz, 1H), 6.80 (td, J = 8.1, 4.8 Hz, 1H), 5.11 (s, 1H), 3.71 (s, 3H), 3.42 (d, J = 2.8 Hz, 3H). ¹³C{¹H} NMR (100 MHz, CDCl₃): δ (ppm) 202.6, 175.2, 169.1, 154.2, 148.4, 146.4, 136.3 (d, $J_{(C-F)} = 221.2$ Hz), 134.4, 133.2, 132.27 (d, $J_{(C-F)} = 8.0$ Hz), 129.3, 129.2, 128.5, 128.0, 126.9, 125.6, 124.3, 123.4 (d, $J_{(C-F)} = 2.9$ Hz), 122.8 (d, $J_{(C-F)} = 6.4$ Hz), 117.7 (d, $J_{(C-F)} = 19.1$ Hz)., 87.5, 77.7, 61.1, 53.0, 29.1. ¹⁹F NMR (377 MHz, CDCl₃): δ (ppm) -136.2. HRMS (ESI TOF) m/z calcd. For C₂₈H₂₀FNO₅SNa [M+Na]⁺ 524.0944, found 524.0944

Methyl-1''-allyl-5'-hydroxy-2'',3-dioxo-3'-phenyl-3*H*-dispiro[benzo[*b*]thiophene-2,2'cyclopentane-1',3''-indolin]-3'-ene-5'-carboxylate (4i)



The compound **4i** was prepared following the general procedure **GP-3**

Yellow solid (27 mg, 46%), dr >20:1, $R_f = 0.46$ (petroleum ether/EtOAc 60:40), MP: 165-167 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.82 (d, J = 7.8 Hz, 1H), 7.46 (t, J = 7.6 Hz, 1H), 7.30 (d, J = 7.7 Hz, 1H), 7.26 (s, 1H), 7.23 – 7.09 (m, 7H), 7.01 (s, 1H), 6.87 (t, J = 7.7 Hz, 1H), 6.78 (d, J = 7.8 Hz, 1H), 5.85 (ddt, J = 15.8, 10.5, 5.4 Hz, 1H), 5.37 (d, J = 17.2 Hz, 1H), 5.23 (d, J = 10.4 Hz, 1H), 5.19 (s, 1H), 4.39 – 4.25 (m, 2H), 3.67 (s, 3H). ¹³C{¹H} NMR (100 MHz, CDCl₃): δ (ppm) 202.8, 175.1, 169.1, 154.3, 148.5, 144.7, 137.3, 135.5, 133.4, 131.5, 129.5, 129.4, 129.0, 128.5, 128.0, 127.6, 126.9, 125.5, 124.2, 122.8, 122.5, 118.1, 109.0, 87.3, 77.9, 64.7, 52.8, 42.9. HRMS (ESI TOF) *m*/*z* calcd. For C₃₀H₂₃NO₅SNa [M+Na]⁺ 532.1195, found 532.1192

Methyl-5'-hydroxy-1''-methyl-2'',3-dioxo-3'-(p-tolyl)-3*H*-dispiro[benzo[*b*]thiophene-2,2'-cyclopentane-1',3''-indolin]-3'-ene-5'-carboxylate (4j)



The compound 4j was prepared following the general procedure GP-3

Yellow solid (25 mg, 44%), dr >20:1, $R_f = 0.34$ (petroleum ether/EtOAc 60:40), MP: 189-191 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.83 – 7.78 (m, 1H), 7.48 – 7.41 (m, 1H), 7.27 – 7.26 (m, 1H), 7.24 – 7.12 (m, 3H), 7.02 (d, J = 0.6 Hz, 4H), 6.97 (d, J = 0.7 Hz, 1H), 6.87 (t, J = 7.7 Hz, 1H), 6.78 (d, J = 7.8 Hz, 1H), 5.15 (d, J = 0.7 Hz, 1H), 3.67 (d, J = 0.7 Hz, 3H), 3.20 (d, J = 0.6 Hz, 3H), 2.28 (s, 3H). ¹³C{¹H} NMR (100 MHz, CDCl₃): δ (ppm) 202.9, 175.5, 169.2, 154.4, 154.4, 148.5, 145.5, 139.1, 137.2, 134.7, 130.5, 129.5, 129.5, 129.2, 128.0, 127.5, 126.8, 126.8, 126.8, 126.8, 126.8, 125.5, 124.2, 122.9, 122.5, 108.1, 87.4, 87.4, 77.7, 64.7, 52.8, 26.5, 21.4. HRMS (ESI TOF) m/z calcd. For C₂₉H₂₄NO₅S [M+H]⁺ 498.1375, found 498.1374

Methyl-5'-hydroxy-3'-(4-methoxyphenyl)-1''-methyl-2'',3-dioxo-3*H*dispiro[benzo[*b*]thiophene-2,2'-cyclopentane-1', 3''-indolin]-3'-ene-5'-carboxylate (4k)



The compound 4k was prepared following the general procedure GP-3

Yellow solid (24 mg, 41%), dr = 90:10. R_f = 0.26 (petroleum ether/EtOAc 60:40), MP: 190-192 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.80 (d, *J* = 8.0 Hz, 1H), 7.46 (t, *J* = 7.6 Hz, 1H), 7.28 (s, 1H), 7.22 (t, *J* = 7.7 Hz, 1H), 7.16 (dd, *J* = 7.7, 4.5 Hz, 2H), 7.08 (d, *J* = 8.7 Hz, 2H), 6.93 (s, 1H), 6.87 (t, *J* = 7.6 Hz, 1H), 6.76 (dd, *J* = 16.5, 8.3 Hz, 3H), 5.12 (s, 1H), 3.74 (s, 3H), 3.67 (s, 3H), 3.20 (s, 3H). ¹³C{¹H} NMR (100 MHz, CDCl₃): δ (ppm) 202.7, 175.4, 169.1, 160.1, 154.2, 147.9, 145.4, 137.1, 133.8, 129.4, 128.1, 127.8, 127.4, 125.7, 125.3, 124.1, 122.8, 122.4, 113.8, 108.0, 87.2, 77.7, 64.6, 55.2, 52.7, 26.4. HRMS (ESI TOF) *m/z* calcd. For C₂₉H₂₄NO₆S [M+H]⁺ 514.1324, found 514.1324

Methyl-3'-(4-bromophenyl)-5'-hydroxy-1''-methyl-2'',3-dioxo-3*H*dispiro[benzo[*b*]thiophene-2,2'-cyclopentane-1',3''-indolin]-3'-ene-5'-carboxylate (4l)



The compound **4**I was prepared following the general procedure **GP-3**

Yellow solid (35 mg, 54%), dr >20:1, $R_f = 0.34$ (petroleum ether/EtOAc 60:40), MP: 205-206 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.77 – 7.70 (m, 1H), 7.43 – 7.36 (m, 1H), 7.30 – 7.25 (m, 2H), 7.21 (s, 1H), 7.18 – 7.05 (m, 3H), 6.96 – 6.89 (m, 3H), 6.81 (td, J = 7.7, 1.0 Hz, 1H), 6.72 (d, J = 7.7 Hz, 1H), 5.09 (s, 1H), 3.60 (s, 3H), 3.13 (s, 3H). ¹³C{¹H} NMR (100 MHz, CDCl₃): δ (ppm) 202.6, 175.4, 169.0, 154.1, 147.5, 145.4, 137.5, 136.0, 132.3, 131.7, 129.6, 129.3, 128.6, 128.0, 127.5, 125.7, 124.2, 123.3, 122.6, 108.2, 87.3, 77.6, 64.7, 52.9, 26.5. HRMS (ESI TOF) *m*/*z* calcd. For C₂₈H₂₁BrNO₅S [M+H]⁺ 562.0324 and 564.0303 found 562.0323 and 564.0317

Methyl-3'-(4-chlorophenyl)-5'-hydroxy-1''-methyl-2'', 3-dioxo-3*H*dispiro[benzo[*b*]thiophene-2,2'-cyclopentane-1', 3''-indolin]-3'-ene-5'-carboxylate (4m)



The compound **4m** was prepared following the general procedure **GP-3**

Yellow solid (28 mg, 47%), dr >20:1, $R_f = 0.37$ (petroleum ether/EtOAc 60:40), MP: 175-176 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.83 – 7.78 (m, 1H), 7.50 – 7.43 (m, 1H), 7.29 – 7.26 (m, 1H), 7.23 – 7.14 (m, 5H), 7.08 – 7.05 (m, 2H), 6.99 (s, 1H), 6.89 (td, J = 7.7, 1.0 Hz, 1H), 6.79 (d, J = 7.8 Hz, 1H), 5.16 (s, 1H), 3.67 (s, 3H), 3.20 (s, 3H). ¹³C{¹H} NMR (100 MHz, CDCl₃): δ (ppm) 202.6, 175.4, 169.0, 154.2, 147.4, 145.5, 137.5, 136.0, 135.1, 131.9, 129.6, 129.3, 128.9, 128.7, 128.4, 128.0, 127.5, 125.7, 124.3, 122.6, 108.2, 87.3, 77.6, 64.7, 52.9, 26.6. HRMS (ESI TOF) *m/z* calcd. For C₂₈H₂₁ClNO₅S [M+H]⁺ 518.0829, found 518.0831

Methyl-3'-(4-fluorophenyl)-5'-hydroxy-1''-methyl-2'', 3-dioxo-3*H*dispiro[benzo[*b*]thiophene-2,2'-cyclopentane-1',3''-indolin]-3'-ene-5'-carboxylate (4n)



The compound 4n was prepared following the general procedure GP-3

Yellow solid (29 mg, 50%), dr > 20:1, $R_f = 0.31$ (petroleum ether/EtOAc 60:40), MP: 202-204 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.73 (d, J = 7.8 Hz, 1H), 7.42 – 7.36 (m, 1H), 7.21 (s, 1H), 7.18 – 7.01 (m, 5H), 6.89 (s, 1H), 6.82 (q, J = 7.7, 6.7 Hz, 3H), 6.72 (d, J = 7.8 Hz, 1H), 5.08 (s, 1H), 3.60 (s, 3H), 3.13 (s, 3H). ¹³C{¹H} NMR (100 MHz, CDCl₃): δ (ppm) 202.7, 175.4, 169.1, 163.2 (d, $J_{(C-F)} = 248.9$ Hz), 154.2, 147.5, 145.5, 137.4, 135.5, 129.6, 129.5 (d,

 $J_{(C-F)} = 3$ Hz), 129.3, 129.0, 128.9 (d, $J_{(C-F)} = 8.3$ Hz), 128.0, 127.5, 125.6, 124.2, 122.7, 122.6, 115.5 (d, $J_{(C-F)} = 21.7$ Hz), 108.2, 87.2, 77.8, 64.7, 52.8, 26.5. ¹⁹F NMR (377 MHz, CDCl₃) δ -112.22. HRMS (ESI TOF) m/z calcd. For C₂₈H₂₀FNO₅S [M+H]⁺ 502.1124, found 502.1121

Methyl-3'-(3-bromophenyl)-5'-hydroxy-1''-methyl-2'',3-dioxo-3*H*dispiro[benzo[*b*]thiophene-2,2'-cyclopentane-1',3''-indolin]-3'-ene-5'-carboxylate (40)



The compound 40 was prepared following the general procedure GP-3

Yellow solid (32mg, 49%), dr >20:1, $R_f = 0.34$ (petroleum ether/EtOAc 60:40), MP: 209-211 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.75 (d, J = 7.6 Hz, 1H), 7.45 – 7.36 (m, 1H), 7.32 (d, J = 8.4 Hz, 2H), 7.22 (s, 1H), 7.18 – 7.06 (m, 3H), 6.99 (t, J = 7.8 Hz, 1H), 6.94 (s, 1H), 6.89 (d, J = 7.8 Hz, 1H), 6.82 (t, J = 7.4 Hz, 1H), 6.72 (d, J = 7.8 Hz, 1H), 5.12 (s, 1H), 3.61 (s, 3H), 3.13 (s, 3H). ¹³C{¹H} NMR (100 MHz, CDCl₃): δ (ppm) 202.5, 175.4, 169.0, 154.2, 147.2, 145.5, 137.5, 136.6, 135.4, 132.0, 130.3, 130.3, 129.9, 129.6, 129.3, 128.1, 127.5, 125.7, 125.4, 124.2, 122.7, 122.6, 122.6, 122.6, 108.2, 100.1, 87.2, 77.6, 64.6, 52.9, 26.6. HRMS (ESI TOF) m/z calcd. For C₂₈H₂₁BrNO₅S [M+H]⁺ 562.0324 and 564.0303 found 562.0337 and 564.0314

Methyl-3'-(3,4-dimethoxyphenyl)-5'-hydroxy-1''-methyl-2'',3-dioxo-3*H*dispiro[benzo[*b*]thiophene-2, 2'-cyclopentane-1', 3''-indolin]-3'-ene-5'-carboxylate (4p)



The compound **4p** was prepared following the general procedure **GP-3**

Yellow solid (25 mg, 40%), dr = 84:16 R_f = 0.15 (petroleum ether/EtOAc 60:40), MP: 222-224 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.76 (d, J = 7.7 Hz, 1H), 7.42 – 7.37 (m, 1H), 7.22 (d, J = 7.2 Hz, 1H), 7.18 – 7.07 (m, 3H), 6.89 (d, J = 11.0 Hz, 1H), 6.82 (t, J = 7.4 Hz, 1H), 6.75 – 6.68 (m, 2H), 6.64 (d, J = 8.4 Hz, 1H), 6.49 (d, J = 1.9 Hz, 1H), 5.10 (s, 1H), 3.75 (s, 3H), 3.60 (s, 3H), 3.41 (s, 3H), 3.14 (s, 3H). ¹³C{¹H} NMR (100 MHz, CDCl₃): δ (ppm) 202.8, 175.5, 169.2, 154.6, 149.7, 148.6, 148.3, 145.5, 137.2, 133.9, 129.6, 129.5, 127.9, 127.6, 126.0, 125.5, 124.2, 122.9, 122.6, 119.6, 111.0, 109.6, 108.2, 87.4, 77.8, 64.6, 56.0, 55.4, 52.8, 26.5. HRMS (ESI TOF) *m*/*z* calcd. For C₃₀H₂₆NO₇S [M+H]⁺ 544.1430, found 544.1427

Copies of ¹H and ¹³C NMR Spectra



¹³C {¹H} NMR (100 MHz, CDCl₃)



SI

Ļ7500















6000



10000

. 9000

8000

. 7000

6000



MeO₂C-

O₂N

Ph

0₀

ċн

____11.28







¹³F NMR (377 MHz, CDCl₃)

-95



⊨ 10000

9000

8000

_ 7000

6000



114 4 11

Ph

0"

Ållyl

ĊН

MeO₂C~





¹³C {¹H} NMR (100 MHz, CDCl₃)



¹³C {¹H} NMR (100 MHz, CDCl₃)

⊢ 30000





28000

























¹⁹ F NMR (377 MHz, CDCl₃)



¹³C {¹H} NMR (100 MHz, CDCl₃)





¹³C {¹H} NMR (100 MHz, CDCl₃)



¹³C {¹H} NMR (100 MHz, CDCl₃)










14000

13000



___ 11.06



120 110 f1 (ppm) ¹³C {¹H} NMR (100 MHz, CDCl₃)

- 300 - 200 - 100 - 0 - -100



¹³C {¹H} NMR (100 MHz, CDCl₃)



¹³C {¹H} NMR (100 MHz, CDCl₃)



4.0

_ 3.5

220

210

9.0

















































Crystallographic data

Molecular Structure of compound 3a using Single Crystal X-ray analysis

Datablock: 3a CCDC 2067873

```
Bond precision: C-C = 0.0049 A
                                     Wavelength=0.71073
               a=9.170(14)
alpha=90
                             b=29.30(4)
Cell:
                                               c=9.624(15)
                             beta=94.36(2)
                                              gamma=90
               100 K
Temperature:
              Calculated
                                      Reported
Volume
              2578(7)
                                      2578(7)
Space group P 21/n
                                      P 21/n
Hall group
             -P 2yn
                                      -P 2yn
Moiety formula C28 H21 N O5, C H Cl3
                                      ?
Sum formula C29 H22 Cl3 N O5
                                      C29 H22 Cl3 N O5
             570.83
                                      570.82
Mr
Dx,g cm-3 1.471
                                      1.471
\mathbf{Z}
              4
                                      4
Mu (mm-1) 0.398
                                      0.398
F000
             1176.0
                                      1176.0
F000'
             1178.28
h,k,lmax
             12,39,12
                                      12,39,12
Nref
              6513
                                      6463
           0.942,0.965
Tmin,Tmax
                                      0.610,0.746
Tmin'
             0.942
Correction method= # Reported T Limits: Tmin=0.610 Tmax=0.746
AbsCorr = MULTI-SCAN
Data completeness= 0.992
                              Theta(max) = 28.473
R(reflections) = 0.0599(3866) wR2(reflections) = 0.1580(6463)
S = 1.029
                        Npar= 347
```

Datablock: 3a- Ellipsoid Plot





Molecular Structure of compound 3v' using Single Crystal X-ray analysis

Datablock: 3v' - CCDC 2067878

```
Wavelength=0.71073
Bond precision: C-C = 0.0030 A
Cell:
               a=9.8464(15) b=16.367(2)
                                                c=14.348(2)
                              beta=94.553(6)
               alpha=90
                                                gamma=90
Temperature:
               100 K
              Calculated
                                       Reported
                                       2305.1(6)
Volume
              2305.0(6)
             P 21/n
                                       P 21/n
Space group
           -P 2yn
Hall group
                                       -P 2yn
Moiety formula C28 H20 Cl N O5
                                       ?
Sum formula C28 H20 Cl N O5
                                       C28 H20 Cl N O5
              485.90
                                       485.90
Mr
              1.400
Dx,g cm-3
                                       1.400
\mathbf{Z}
              4
                                       4
             0.207
                                       0.207
Mu (mm-1)
F000
              1008.0
                                       1008.0
F000'
              1009.08
h,k,lmax
             11,19,17
                                       11,19,17
Nref
             4066
                                       4056
Tmin,Tmax
             0.973,0.982
                                       0.621,0.746
Tmin'
              0.973
Correction method= # Reported T Limits: Tmin=0.621 Tmax=0.746
AbsCorr = MULTI-SCAN
Data completeness= 0.998 Theta(max) = 25.025
R(reflections) = 0.0416( 3245)
                              wR2(reflections) = 0.0954(4056)
S = 1.051
                        Npar= 318
```







Molecular Structure of compound 4a using Single Crystal X-ray analysis

Datablock: 4a- CCDC 2067874

Bond precision: C-C = 0.0030 A Wavelength=0.71073 Cell: a=9.9440(6) b=10.1014(5) c=11.6132(6) alpha=79.844(2) beta=79.371(2) gamma=84.323(2) Temperature: 100 K Calculated Reported 1125.89(11) Volume 1125.89(11) P -1 Space group P -1 Hall group -P 1 -P 1 Moiety formula C28 H21 N O5 S C28 H21 N O5 S Sum formula C28 H21 N O5 S C28 H21 N O5 S 483.52 483.52 Mr Dx,g cm-3 1.426 1.426 \mathbf{Z} 2 2 0.186 Mu (mm-1) 0.186 F000 504.0 504.0 F000' 504.49 h,k,lmax 13,13,15 13,13,15 Nref 5645 5434 Tmin,Tmax 0.972,0.983 0.610,0.746 Tmin' 0.972 Correction method= # Reported T Limits: Tmin=0.610 Tmax=0.746 AbsCorr = MULTI-SCAN Data completeness= 0.963 Theta(max) = 28.388 R(reflections) = 0.0503(4166) wR2(reflections) = 0.1532(5434) S = 0.910Npar= 319

Datablock: 4a- Ellipsoid Plot





Molecular Structure of compound 4c using Single Crystal X-ray analysis

Datablock: 4c- CCDC 2067877

Bond precision: C-C = 0.0022 A Wavelength=1.54178 Cell: a=9.4270(5) b=10.2071(6) c=13.7551(8) alpha=76.432(2) beta=74.927(2) gamma=79.643(2) Temperature: 100 K Calculated Reported Volume 1232.36(12)1232.36(12)Space group P -1 P -1 Hall group -P 1 -P 1 Moiety formula C29 H23 N 06 S C29H23No6S Sum formula C29 H23 N 06 S C29 H23 N 06 S Mr 513.54 513.54 Dx,g cm-3 1.384 1.384 2 Ζ 2 Mu (mm-1) 1.556 1.556 F000 536.0 536.0 F000' 538.31 h,k,lmax 11,12,16 11,12,16 Nref 4338 4268 Tmin,Tmax 0.817,0.883 0.622,0.754 Tmin' 0.817 Correction method= # Reported T Limits: Tmin=0.622 Tmax=0.754 AbsCorr = MULTI-SCAN Data completeness= 0.984 Theta(max) = 66.593 R(reflections)= 0.0364(3919) wR2(reflections) = 0.0937(4268) S = 1.031Npar= 339

Datablock: 4c- Ellipsoid Plot



